These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21864451)

  • 1. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
    Sert A; Gokcen C; Aypar E; Odabas D
    Cardiol Young; 2012 Apr; 22(2):158-61. PubMed ID: 21864451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
    Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
    J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
    Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Life-threatening QT prolongation in a boy with attention-deficit/hyperactivity disorder on atomoxetine.
    Yamaguchi H; Nagumo K; Nakashima T; Kinugawa Y; Kumaki S
    Eur J Pediatr; 2014 Dec; 173(12):1631-4. PubMed ID: 24233333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased blood pressure and atomoxetine.
    Dworkin N
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510. PubMed ID: 15908831
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
    Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
    Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.
    Donner R; Michaels MA; Ambrosini PJ
    Biol Psychiatry; 2007 Mar; 61(5):706-12. PubMed ID: 16899230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
    Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
    Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
    Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
    J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy.
    Torres A; Whitney J; Rao S; Tilley C; Lobel R; Gonzalez-Heydrich J
    Epilepsy Behav; 2011 Jan; 20(1):95-102. PubMed ID: 21146461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
    Wernicke JF; Kratochvil CJ
    J Clin Psychiatry; 2002; 63 Suppl 12():50-5. PubMed ID: 12562062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.
    Zeiner P; Gjevik E; Weidle B
    Acta Paediatr; 2011 Sep; 100(9):1258-61. PubMed ID: 21392103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.